CN1602879A - 抑制骨吸收的方法 - Google Patents

抑制骨吸收的方法 Download PDF

Info

Publication number
CN1602879A
CN1602879A CNA2004100557346A CN200410055734A CN1602879A CN 1602879 A CN1602879 A CN 1602879A CN A2004100557346 A CNA2004100557346 A CN A2004100557346A CN 200410055734 A CN200410055734 A CN 200410055734A CN 1602879 A CN1602879 A CN 1602879A
Authority
CN
China
Prior art keywords
purposes
bis
phosphonic acids
alendronic acid
medication
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004100557346A
Other languages
English (en)
Chinese (zh)
Inventor
A·G·戴福蒂斯
A·C·桑托拉二世
A·J·雅特斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27451690&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1602879(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9717590.5A external-priority patent/GB9717590D0/en
Priority claimed from GBGB9717850.3A external-priority patent/GB9717850D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of CN1602879A publication Critical patent/CN1602879A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Saccharide Compounds (AREA)
  • Fittings On The Vehicle Exterior For Carrying Loads, And Devices For Holding Or Mounting Articles (AREA)
  • Pit Excavations, Shoring, Fill Or Stabilisation Of Slopes (AREA)
  • Aiming, Guidance, Guns With A Light Source, Armor, Camouflage, And Targets (AREA)
CNA2004100557346A 1997-07-22 1998-07-17 抑制骨吸收的方法 Pending CN1602879A (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US5335197P 1997-07-22 1997-07-22
US60/053351 1997-07-22
US5353597P 1997-07-23 1997-07-23
US60/053535 1997-07-23
GBGB9717590.5A GB9717590D0 (en) 1997-08-20 1997-08-20 Oral method for treating or preventing abnormal bone resorption
GB9717590.5 1997-08-20
GB9717850.3 1997-08-22
GBGB9717850.3A GB9717850D0 (en) 1997-08-22 1997-08-22 Oral method for treating or preventing abnormal bone resorption

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CNB988074737A Division CN1166365C (zh) 1997-07-22 1998-07-17 阿仑膦酸的药物组合物及其在制备抑制人的骨吸收的药物中的用途

Publications (1)

Publication Number Publication Date
CN1602879A true CN1602879A (zh) 2005-04-06

Family

ID=27451690

Family Applications (3)

Application Number Title Priority Date Filing Date
CNA2004100557346A Pending CN1602879A (zh) 1997-07-22 1998-07-17 抑制骨吸收的方法
CNB2004100557350A Expired - Lifetime CN1299689C (zh) 1997-07-22 1998-07-17 阿仑膦酸在制备抑制骨吸收药物中的用途
CNB988074737A Ceased CN1166365C (zh) 1997-07-22 1998-07-17 阿仑膦酸的药物组合物及其在制备抑制人的骨吸收的药物中的用途

Family Applications After (2)

Application Number Title Priority Date Filing Date
CNB2004100557350A Expired - Lifetime CN1299689C (zh) 1997-07-22 1998-07-17 阿仑膦酸在制备抑制骨吸收药物中的用途
CNB988074737A Ceased CN1166365C (zh) 1997-07-22 1998-07-17 阿仑膦酸的药物组合物及其在制备抑制人的骨吸收的药物中的用途

Country Status (31)

Country Link
EP (5) EP1175904B8 (enExample)
JP (2) JP3479780B2 (enExample)
KR (3) KR20030097611A (enExample)
CN (3) CN1602879A (enExample)
AT (2) ATE357921T1 (enExample)
AU (1) AU8493698A (enExample)
BG (1) BG66282B1 (enExample)
BR (1) BR9810779A (enExample)
CA (1) CA2294595C (enExample)
CY (2) CY1107535T1 (enExample)
DE (6) DE69803291T2 (enExample)
DK (2) DK0998292T3 (enExample)
EA (1) EA004544B2 (enExample)
EE (1) EE05603B1 (enExample)
ES (3) ES2253136T1 (enExample)
HK (4) HK1042230A1 (enExample)
ID (1) ID24096A (enExample)
IL (1) IL133535A0 (enExample)
IS (3) IS5315A (enExample)
LU (2) LU91222I2 (enExample)
NL (2) NL300223I1 (enExample)
NO (1) NO20000323L (enExample)
NZ (1) NZ501807A (enExample)
PL (1) PL195272B1 (enExample)
PT (2) PT998292E (enExample)
SG (2) SG139556A1 (enExample)
SI (1) SI0998292T1 (enExample)
SK (1) SK932000A3 (enExample)
TR (1) TR200000145T2 (enExample)
UY (1) UY25950A1 (enExample)
WO (1) WO1999004773A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3219402B2 (ja) 1998-12-25 2001-10-15 山之内製薬株式会社 多発性骨髄腫の骨病変治療用医薬組成物
EP1178810B8 (en) * 1999-05-21 2005-07-27 Novartis AG Use of bisphosphonic acids for treating angiogenesis
EP1114642B1 (en) * 1999-07-19 2010-01-06 Toray Industries, Inc. Drugs for periodontal diseases
WO2001046040A1 (en) 1999-12-20 2001-06-28 Merck & Co., Inc. Blister package for pharmaceutical treatment card
WO2001045636A1 (en) * 1999-12-20 2001-06-28 Merck & Co., Inc. Pharmaceutical kit
WO2001076577A2 (en) * 2000-04-07 2001-10-18 The Board Of Regents Of The University Of Texas System Unique compositions of zwitterionic phospholipids and bisphosphonates and use of the compositions as bisphosphate delivery systems with reduced gi toxicity
DK1296689T3 (da) 2000-06-20 2005-11-28 Novartis Ag Fremgangsmåde til indgivelse af bisphosphonater
EP1591122B1 (en) * 2000-06-20 2012-09-26 Novartis AG Method of administering bisphosphonates
US6638920B2 (en) * 2000-07-21 2003-10-28 Merck & Co., Inc. Compositions and methods of preventing or reducing the risk or incidence of skeletal injuries in horses
SE0101379D0 (sv) * 2001-04-18 2001-04-18 Diabact Ab Komposition som hämmar utsöndring av magsyra
BR0209360A (pt) * 2001-05-02 2004-06-08 Novartis Ag Método de administração de bisfosfonatos por inalação no tratamento ou prevenção de reabsorção óssea e osteoporose
BR0308901A (pt) * 2002-05-10 2005-01-04 Hoffmann La Roche ácidos bisfosfÈnicos para tratamento e prevenção de osteoporose
SE0203065D0 (sv) 2002-10-16 2002-10-16 Diabact Ab Gastric acid secretion inhibiting composition
AU2004273672A1 (en) * 2003-09-19 2005-03-31 Wisconsin Alumni Research Foundation Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and a bisphosphonate
WO2005072747A1 (ja) * 2004-02-02 2005-08-11 Ono Pharmaceutical Co., Ltd. 骨吸収抑制剤
NZ567200A (en) * 2005-09-16 2010-08-27 Selamine Ltd Bisphosphonate formulation
US9592195B2 (en) * 2010-12-06 2017-03-14 Effrx Pharmaceuticals Sa Stable effervescent bisphosphonate formulations with rapid solubilization characteristics
CN106924257B (zh) * 2017-03-14 2019-11-19 湖南赛隆药业有限公司 质子泵抑制剂和抗骨质疏松药的复合物及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL84731A0 (en) * 1986-12-19 1988-05-31 Norwich Eaton Pharma Heterocycle-substituted diphosphonic acids and salts and esters and pharmaceutical compositions containing them
SE8704436D0 (sv) * 1987-11-13 1987-11-13 Pm Konsult Handelsbolag Anvendning av antisekretoriska substanser for nya indikationer
ATE122228T1 (de) * 1991-07-01 1995-05-15 Gergely Gerhard Verfahren zur herstellung einer pharmazeutischen zubereitung mit wenigstens zwei verschiedenen wirkstoffen und verwendung einer solchen zubereitung.
CZ282760B6 (cs) * 1991-11-22 1997-09-17 Procter And Gamble Pharmaceuticals, Inc. Risedronátové prostředky se zpožděným uvolňováním
US5270365A (en) * 1991-12-17 1993-12-14 Merck & Co., Inc. Prevention and treatment of periodontal disease with alendronate
US5294433A (en) * 1992-04-15 1994-03-15 The Procter & Gamble Company Use of H-2 antagonists for treatment of gingivitis
ES2111163T3 (es) * 1992-06-30 1998-03-01 Procter & Gamble Pharma Uso de fosfonatos para el tratamiento de la osteoporosis.
US5431920A (en) * 1993-09-21 1995-07-11 Merck Frosst, Canada, Inc. Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents
US5646134A (en) * 1994-04-21 1997-07-08 Merck & Co., Inc. Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices
EP0831843A1 (en) * 1995-06-06 1998-04-01 Merck & Co., Inc. Bisphosphonate therapy for bone loss associated with rheumatoid arthritis
DE69726879T2 (de) * 1996-05-17 2004-10-14 Merck & Co., Inc. Biphosphonat-formulierung mit brausewirkung

Also Published As

Publication number Publication date
EP0998292B1 (en) 2001-11-21
JP2002502433A (ja) 2002-01-22
CN1299689C (zh) 2007-02-14
IS5315A (is) 1999-12-21
TR200000145T2 (tr) 2000-05-22
EP1175904A2 (en) 2002-01-30
ATE357921T1 (de) 2007-04-15
JP2005068010A (ja) 2005-03-17
CN1265035A (zh) 2000-08-30
EP1175904B8 (en) 2007-05-09
ID24096A (id) 2000-07-06
PT1175904E (pt) 2007-04-30
EP1175903A3 (en) 2002-12-18
DK1175904T3 (da) 2007-05-07
PL338635A1 (en) 2000-11-06
EE200000040A (et) 2000-10-16
EP1151752A2 (en) 2001-11-07
EP0998292A2 (en) 2000-05-10
NZ501807A (en) 2003-02-28
SK932000A3 (en) 2000-09-12
HK1040494A1 (en) 2002-06-14
EA004544B1 (ru) 2004-06-24
CN1602880A (zh) 2005-04-06
EP1132088A3 (en) 2002-04-24
KR100391732B1 (ko) 2003-07-16
ATE209037T1 (de) 2001-12-15
DE69837450D1 (de) 2007-05-10
SG109478A1 (en) 2005-03-30
KR20030097611A (ko) 2003-12-31
EA200000151A1 (ru) 2000-10-30
BG66282B1 (bg) 2013-01-31
DE122006000009I1 (de) 2006-06-14
EP1175904B1 (en) 2007-03-28
CN1166365C (zh) 2004-09-15
CY2007022I2 (el) 2012-01-25
ES2269014T1 (es) 2007-04-01
DE122007000063I1 (de) 2007-12-20
ES2269014T3 (es) 2007-05-01
AU8493698A (en) 1999-02-16
NO20000323L (no) 2000-03-20
LU91364I2 (fr) 2007-11-12
EP1132088A2 (en) 2001-09-12
DE01201913T1 (de) 2007-02-08
PT998292E (pt) 2002-04-29
IS7230A (is) 2004-04-21
KR20010022110A (ko) 2001-03-15
CA2294595C (en) 2001-08-21
EP1175904A3 (en) 2002-12-18
LU91222I2 (fr) 2006-04-18
ES2253136T1 (es) 2006-06-01
IS7231A (is) 2004-04-21
EA004544B2 (ru) 2006-12-29
NL300292I1 (nl) 2007-11-01
DE69803291D1 (de) 2002-02-21
ES2164447T3 (es) 2002-02-16
HK1024166A1 (en) 2000-10-05
CY2007022I1 (el) 2012-01-25
WO1999004773A2 (en) 1999-02-04
CY1107535T1 (el) 2012-01-25
NO20000323D0 (no) 2000-01-21
SG139556A1 (en) 2008-02-29
HK1042232A1 (en) 2002-08-09
NL300223I1 (nl) 2006-04-03
PL195272B1 (pl) 2007-08-31
JP3479780B2 (ja) 2003-12-15
SI0998292T1 (en) 2002-04-30
DE69837450T2 (de) 2007-08-23
UY25950A1 (es) 2000-09-29
EP1175903A2 (en) 2002-01-30
BG104093A (en) 2000-10-31
WO1999004773A9 (en) 1999-10-28
WO1999004773A3 (en) 1999-04-15
DE69803291T2 (de) 2002-08-08
HK1040495A1 (en) 2002-06-14
KR20030097610A (ko) 2003-12-31
HK1042230A1 (en) 2002-08-09
EP1151752A3 (en) 2002-12-18
IL133535A0 (en) 2001-04-30
DE01201911T1 (de) 2007-10-18
BR9810779A (pt) 2000-07-25
DK0998292T3 (da) 2002-05-13
EE05603B1 (et) 2012-12-17
CA2294595A1 (en) 1999-02-04

Similar Documents

Publication Publication Date Title
CN1299689C (zh) 阿仑膦酸在制备抑制骨吸收药物中的用途
US6544967B2 (en) Method for inhibiting bone resorption
US6015801A (en) Method for inhibiting bone resorption
US6465443B2 (en) Method for inhibiting bone resorption
CN1919200A (zh) 抑制骨吸收的方法
HK1103223A (en) Method for inhibiting bone resorption
AU741818B2 (en) Method for inhibiting bone resorption
AU2451102A (en) Method for inhibiting bone resorption
AU2005227418A1 (en) Method for inhibiting bone resorption
CA2349733A1 (en) Inhibition bone resorption
HUP0004653A2 (hu) Biszfoszfonátok alkalmazása csontreszorpció gátlására szolgáló gyógyszerkészítmények előállítására

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication